HCM
PASG icon

Highline Capital Management’s Passage Bio PASG Stock Holding History

Highline Capital Management’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-61,793
Closed -$1.54M – 13
2022
Q3 		$1.54M Hold
61,793
– – 2.89% 13
2022
Q2 		$2.92M Hold
61,793
– – 5.04% 9
2022
Q1 		$3.83M Hold
61,793
– – 4.65% 9
2021
Q4 		$7.85M Buy
61,793
+2,500
+4% +$408K 6.91% 9
2021
Q3 		$11.8M Buy
59,293
+9,418
+19% +$2.25M 9.97% 5
2021
Q2 		$13.2M Buy
49,875
+6,328
+15% +$1.96M 11.02% 2
2021
Q1 		$15.2M Buy
43,547
+13,435
+45% +$5.74M 10.38% 1
2020
Q4 		$15.4M Buy
30,112
+106
+0.4% +$42.4K 7.53% 2
2020
Q3 		$7.87M Sell
30,006
-2,374
-7% -$817K 7.88% 6
2020
Q2 		$17.7M Buy
32,380
+13,913
+75% +$6.26M 14.38% 1
2020
Q1 		$5.82M Buy
+18,467
New +$5.78M 1.42% 20

Other funds holding PASG

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Highline Capital Management's PASG Position: Q4 2022 in Review

Highline Capital Management sold out of Passage Bio (PASG) in Q4 2022, closing a stake of 61,793 shares — an estimated $1.54M sold.

Highline Capital Management first reported a position in PASG in Q1 2020 and held it in 11 quarters. The position peaked at $17.7M in Q2 2020. 67 funds tracked by Wall St. Rank hold PASG as of Q4 2022.

  • Highline Capital Management reported no remaining Passage Bio position as of Q4 2022 after selling out during the quarter.
  • Highline Capital Management sold 61,793 Passage Bio shares in Q4 2022, an estimated $1.54M.
  • Highline Capital Management first reported a position in Passage Bio in Q1 2020 and held it in 11 quarters.
  • Highline Capital Management's Passage Bio position peaked at $17.7M in Q2 2020.
  • 67 funds tracked by Wall St. Rank held Passage Bio as of Q4 2022.

Based on Highline Capital Management's 13F filing for Q4 2022.